



S.S. FORMAZIONE PERMANENTE E RAPPORTI CON L'UNIVERSITA'

Evento Formativo Residenziale

**CRPT-PROGRAMMA REGIONALE DI SCREENING PER IL CERVICOCARCINOMA
PREVENZIONE SERENA: LO SCREENING A PARTIRE DA PAROLE CHIAVE
– WORKSHOP 2022**

Prestazioni aggiuntive e strategie


Carlo Senore

SSD Epidemiologia e screening - CPO




Impatto diverse strategie di ripresa

Effects of cancer screening restart strategies after COVID-19 disruption

Lindy M. Kregting¹, Sylvia Kaljouw¹, Lucie de Jonge¹, Erik E. L. Jansen¹, Elisabeth F. P. Peterse¹, Eveline A. M. Heijnsdijk¹, Nicolien T. van Ravesteijn¹, Iris Lansdorp-Vogelaar¹ and Inge M. C. M. de Kok¹



Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses

Alejandra Castanon ¹, Matejka Rebolj¹, Francesca Pesola ¹ and Peter Sasieni ¹

British Journal of Cancer (2021) 124:1361–1365;

The scenario in which some women miss one screening cycle creates inequalities

- They would have higher rates of excess cancer: 41.5 per 100,000 delayed for screened women compared to those with a 6-month delay (5.9 per 100,000).

CONCLUSION: To ensure equity for those affected by COVID-19 related screening delays additional screening capacity will need to be paired with prioritizing the screening of overdue women.

Cervical screening during the COVID-19 pandemic: optimising recovery strategies

Lancet Public Health 2021;
6: e522-27

Alejandra Castanon, Matejka Rebolj, Emily Annika Burger*, Inge M C M de Kok*, Megan A Smith*, Sharon J B Hanley*, Francesca Maria Carozzi†, Stuart Peacock†, James F O'Mahony

Risk-based triage

Age	Deprioritise women in age groups in which risk of cancer from missed screens is low
Previous screen history	Deprioritise women with a previous negative test by extending the interval between screening tests
HPV vaccination status	Deprioritise women who are vaccinated against HPV

- Dare la priorità a donne non screenate che hanno superato l'età di invito a causa dei ritardi dovuti al COVID


Priorità

- Estensione a 6 anni dell'intervallo per il reinvito per le donne con precedente

HPV negativo


Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

*Guglielmo Ronco, Joakim Dillner, K Miriam Elfström, Sara Tunesi, Peter J F Snijders, Marc Arbyn, Henry Kitchener, Nereo Segnan, Clare Gilham, Paolo Giorgi-Rossi, Johannes Berkhof, Julian Peto, Chris J L M Meijer, and the International HPV screening working group**




- Sospensione temporanea del blocco dell'invito a 65 anni
- Rinvio dell'invito alla prima coorte delle donne vaccinate al 2023

Andamento inviti –esami 2019-2020-2021




Ritardo inviti




Copertura inviti al 30/9

2019-2022




Tipologia di invito


% di invitate non aderenti round precedenti



% di invitate aderenti round precedenti




Ritardo esami




Ritardo (mesi standard) per trimestre (2020-2021)

Screening tumore della cervice uterina




Obiettivi attività per Azienda -2021




Copertura esami al 30/9

2019-2022



Copertura esami al 30/9/2022

Confronto 2019



Grazie a

Paola Armaroli

Marco Calcagno

Cristiano Piccinelli

Grazie per l'attenzione